ArticleJournal of atherosclerosis and thrombosis2026
An Elevated Serum Apolipoprotein C-III Concentration is Associated with the Risk of Coronary Heart Disease in a Japanese General Population. The Hidaka Cohort Study.
Article in Journal of atherosclerosis and thrombosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimApolipoprotein CIII (ApoC-III) is a lipid-associated protein crucial for the lipid metabolism. Recent studies have shown that ApoC-III also plays a role in vascular dysfunction and the development of coronary heart disease (CHD). This study examined the hypothesis that the serum ApoC-III concentration is associated with the future risk of CHD in a general Japanese population.
methodsWe prospectively studied 1,676 individuals (1,005 women, 671 men; mean age 57.1 years) in a rural community in Japan. In the 1993 baseline survey, anthropometric examinations, current smoking status, blood pressure, and serum concentrations of lipids and apolipoproteins were assessed. During the follow-up period of 10.9 years (interquartile range 10.8 - 11.1), 48 participants developed CHD, including 18 fatal and non-fatal myocardial infarction patients and 30 sudden death cases.
resultsIn the age- and sex-adjusted analysis, we did not find any association between the baseline serum ApoC-III concentration and the risk of CHD and sudden death (HR 2.11, CI 0.88 - 5.03, P = 0.094). However, in a multivariable analysis adjusted for age, sex, the presence of hypertension, presence of diabetes mellitus, current smoking status, total cholesterol, high-density lipoprotein cholesterol, and triglycerides, serum ApoC-III concentration was significantly associated with the risk of CHD and sudden death (HR 3.59, CI 1.05 - 12.3, P = 0.041).
conclusionSerum ApoC-III concentration was independently associated with the risk of CHD and sudden death in a general Japanese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.